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Abstract
Objectives. The aim was to determine whether assisted reproductive technologies (ARTs) confer ad-
ditional risk in rheumatic patients (in terms of disease flare and fetal–maternal complications) and
whether, if performed, their efficacy is affected by maternal disease.
Methods. Sixty infertile rheumatic women undergoing 111 ART cycles were included. Clinical preg-
nancy rate, live birth rate, maternal disease flares and maternal–fetal complications were recorded.
Results. One hundred and eleven ART cycles in 60 women were analysed. We reported 46 pregnan-
cies (41.4%), 3 (3.1%) cases of ovarian hyperstimulation syndrome and no cases of thrombosis during
stimulation, pregnancy and puerperium. One or more maternal complication was reported in 13
(30.2%) pregnancies, and fetal complications occurred in 11 fetuses (21.1%). The live birth rate was
98%, but we reported three (6%) perinatal deaths in the first days of life. During puerperium, we
recorded one (2.5%) post-partum haemorrhage and one (2.5%) articular flare.
Conclusion. The safety and efficacy of the ARTs, demonstrated in the general population, seems to
be confirmed also in rheumatic patients. No evidence was found to advise against their application,
and the choice of therapy should be made depending on the patient’s risk profile, irrespective of
whether the pregnancy is natural or artificial induced.
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Key messages
. The safety of assisted reproductive technologies seems to be confirmed also in rheumatic patients.
. Fetal–maternal complications are in line with those observed in spontaneous gestation in rheumatic patients.
. Efficacy of assisted reproductive technologies in rheumatic patients does not seem to be adversely affected by
maternal disease.
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Introduction
The World Health Organization defines infertility as ‘a
disease of the reproductive system defined by the failure
to achieve a clinical pregnancy after 12months or more
of regular unprotected sexual intercourse’ [1]. It has
been estimated that !12–15% of couples of reproduc-
tive age suffer from this condition, and it is therefore not
surprising that such a high percentage may also include
patients with rheumatic diseases (RDs).
Infertility is likely to be multifactorial in RDs; chronic
disease and its treatment can have a negative impact
on natural fertility, in addition to all the risk factors iden-
tified in the general population (increased maternal age,
endometriosis, tobacco use, alteration of the BMI,
coeliac disease and dysthyroidisms) [2].
In a Norwegian population-based study, a reduced
number of births, longer intervals between pregnancies
and shorter reproductive periods were shown in women
with RDs when compared with healthy controls [3].
Besides a true reduction in fertility [4], this finding could
also be attributable to personal choice of the patients [5]
(physical limitations [6], emotional states including anxi-
ety and depression [7], fear of drug side effects on the
fetus and/or transmission of the disease to the baby,
and fear of not being able to take care of the baby).
The ovarian reserve was investigated in some RDs by
means of circulating levels of the anti-Mu¨llerian hormone
(AMH). An actual decrease in AMH levels has been dem-
onstrated in SLE [8, 9], APS [10], AS [11], Behc¸et disease
[12], Takayasu arteritis [13] and DM [14], whereas contra-
dictory results have emerged regarding RA [11, 15, 16].
Regarding the influence of autoantibodies, a patho-
genic role has been confirmed for anti-sperm [17] and
anti-ovarian antibodies [18] only, and their presence rep-
resents an indication for medical immunosuppressive
treatment and the use of assisted reproductive technol-
ogies (ARTs) [19].
Only fragmentary and sometimes contradictory data
are available for aPL [20].
Insufficient data are available to draw definitive con-
clusions about a possible role of ANA and other autoan-
tibodies, although it seems unlikely that they might
cause infertility.
DMARDs, such as MTX, MMF, AZA, CSA and
tacrolimus, do not seem to affect AMH levels [21].
Conversely, the dose- and age-dependent effects of CYC
are well documented both on the decrease of AMH [22]
and in the induction of premature ovarian failure [21].
No studies are available on the effects of anti-TNF on
female fertility, whereas no influence on sperm quality of
exposed men was found [21]. Regarding the use of
glucocorticoids, no clear influence has been demon-
strated on fertility [21].
An increasing number of women with RDs have been
approaching ARTs, posing a problem of counselling on
two major issues: the effect of ARTs (and, in particular, of
the hormonal stimulation, if required) on the underlying dis-
ease; and the effect of the underlying disease
(autoantibodies, chronic inflammation, drugs, etc.) on the
efficacy of the technology itself, in terms of induction of a
pregnancy.
Given the paucity of the literature on this topic [23–31],
the aim of the present study was to investigate a cohort of
patients with different RDs undergoing ARTs, in an attempt
to answer these questions.
Methods
This is a multicentre, observational, non-interventional,
retrospective study. We included consecutive patients
with RDs (diagnosis according to internationally vali-
dated criteria) prospectively followed up during one or
more cycles of ARTs at the pregnancy clinics of
Brescia, Padua, Pavia, Rome and Milan, Italy.
Infertility has been defined as primary if diagnosed in
a patient who had never spontaneously conceived and
as secondary if the problem arose after one or more
spontaneous pregnancies.
Pregnancy trimesters were defined as follows: first tri-
mester: up to 13þ6 weeks of gestation; second: from
14th to 26þ6 weeks; third: after 27th week.
Disease activity was assessed according to medical
judgement and, when available, using specific indexes.
For SLE, we used the SLEDAI at conception and the
SLEDAI-P (modified for pregnancy) during gestation [32];
a cut-off value of six was arbitrarily chosen to define the
disease as active. For chronic arthritis or CTDs with ar-
ticular involvement, the DAS-28 (remission for values
<2.6, low disease activity for values between 2.6 and
3.2, medium between 3.2 and 5.1 and high disease ac-
tivity for values >5.1) was used. A flare was defined
according to disease indexes, when available, or to
medical judgement.
ART procedures have been classified as unstimulated
(applied during a natural menstrual cycle without ovarian
stimulation) or stimulated (when ovarian stimulation was
performed before the sperm or the embryo transfer).
In particular, we included the following protocols: the
gonadotrophin-only protocol (with human menopausal gona-
dotrophins, follicle-stimulating hormone or luteinizing
hormone); the agonist protocol [with the administration of a
gonadotrophin-releasing hormone (GnRH) agonist: triptorelin,
leuprorelin or buserelin]; the antagonist protocol (with the
administration of a GnRH antagonist: ganirelix or cetrorelix);
the clomiphene protocol (‘mild ovarian stimulation’ with
clomiphene citrate, without gonadotrophins); the homo-
logous protocol when the sperm was obtained from the
partner [intrauterine insemination (IUI)]; and the heterologous
protocol when the semen or the oocyte was obtained from
a donor [in vitro fertilization (IVF) with embryo transfer or
intracytoplasmic sperm injection (ICSI) or embryo donation].
The previous obstetrical history and the observed
pregnancy outcome were defined as follows: at term de-
livery: vaginal or caesarean delivery occurred beyond
the 36th week of gestation; preterm delivery: occurred
before the 36th week of gestation; miscarriage: fetal
death occurred within the 10th week of gestation;
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intrauterine death: fetal death occurred after the 10th
week of gestation; and perinatal death: occurred by day
28 after the birth of a live fetus, premature or at term.
The main maternal–fetal complications assessed were
defined as follows: pre-eclampsia: resting blood pressure
of #140/90mmHg on two occasions #4h apart in previ-
ously normotensive women and the development of de
novo proteinuria (#300mg/24 h) or a twofold worsening in
women without and with pre-existing proteinuria, respec-
tively, after 20weeks of pregnancy [33]; thrombosis: one
or more arterial or venous thrombotic event, confirmed by
appropriate diagnostic images; intrauterine growth
restriction: rate of fetal growth that is less than normal for
the growth potential; oligohydramnios: decrease in the am-
niotic fluid to <500ml until its almost complete absence
(anhydramnios); and pre-labour rupture of membranes.
Our main efficacy outcome was the induction of a preg-
nancy, and our main safety outcome was the onset of ma-
ternal disease flares and of fetal–maternal complications.
The study was performed according to the Declaration of
Helsinki. Approval from the ASST Spedali Civili of Brescia
ethical committee was obtained (protocol n’2170, 20
October 2015). All patients gave their informed consent
before their inclusion in the study.
Statistical analysis
Categorical variables were reported as a proportion and/or
percentage. Continuous variables were reported as the
median [interquartile range (IQR)] value. Fisher’s exact or
v2 test for categorical variables and Student’s t test or the
Wilcoxon–Mann–Whitney test for continuous variables
were used as appropriate. Multivariate analysis was per-
formed. Associations between variables were examined by
Pearson correlation test. Values of P < 0.05 were consid-
ered significant.
Results
We analysed 111 ART procedures performed in 60
women from 1997 to 2016. The main features of the co-
hort are available in Table 1.
Procedures analysis
One hundred and eleven ARTs cycles were analysed: 13
IUI, 44 IVF (3 heterologous), 53 ICSI (14 heterologous)
and 1 embryo donation. Procedures were unstimulated
(during a natural cycle) in 15 (13.5%) cases and
TABLE 1 Main clinical and serological features of the 60 women included in the study
60 women undergoing 111 ART attempts
Diagnosis 22 SLE (2þAPS), 12 UCTD, 6 PAPS, 8 RA, 4 AS, 2 SS, 1 DM, 1 PA, 1 Takayasu ar-
teritis, 1 EGPA, 1 Behc¸et disease, 1 SSc
Maternal age at the time of ART, median
(range), years
37 (19–45)
Disease duration at the time of ART,
median (range), years
6 (1–22)
Disease activity at the time of procedure n¼3 (active arthritis, in 1 RA patient, 1 UCTD patient and 1 SLE patient), all with
low disease activity
Additional risk factors: abdominal
pelvic surgery, uterine myomas,
endometriosis, POCS, obesity,
hormonal and anatomical
alterations
n¼26 (43.3%):
. Single: 21 (80.8%)
. Multiple: 5 (19.2%)
Type of diagnosed infertility % Primary: 40 (68%): 5 (12.5%) male, 6 (15%) female, 1 (2.5%) mixed maleþfemale,
28 (70%) idiopathic
% Secondary: 20 (32%): 3 (15%) female, 17 (85%) idiopathic
Thyroid alterations, available in 54 (90%)
patients
n¼27 (50%):
. isolated autoantibody positivity with euthyroidism: 7 (25.9%)
. hypothyroidism on replacement therapy: 20 (74.1%)
Autoantibodies ANA: n¼44 (73.3%); anti-ENA: n¼23 (38.3%). In detail: 11 anti-Ro-SSA, 6 anti-
Ro-SSAþanti-La-SSB, 3 anti-U1RNP, 1 anti-centromere, 1 anti-Ro-SSAþanti-
Smþanti-U1RNP, 1 anti-Ro-SSAþanti-centromere
aPL: n¼23 (38.3%); single positivity in 14 (23.3%), double in 6 (10%), triple in 3
(5%)
Inherited thrombophilia, available in 28
(46.7%) patients
n¼16 (58.5%): single: 94.4%; multiple: 5.6%. In detail:
. MTHFR mutation: n¼12, 10 heterozygous and 2 homozygous;
. Factor V Leiden: n¼5, all heterozygous;
. Factor II mutation: n¼1;
. PAI mutation: n¼1
Abbreviations: ART: assisted reproductive technology; EGPA: eosinophilic granulomatosis with polyangiitis; MTHFR: methy-
lene tetrahydrofolate reductase; PA: psoriasic arthritis; PAI: plasminogen activator inhibitor; PAPS: primary APS; POCS:
polycystic ovary syndrome.
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performed after ovarian stimulation in 96 (86.5%): with
the GnRH agonist protocol in 59 (61.4%), with the
GnRH antagonist protocol in 26 (26.8%), with gonado-
trophins only in 7 (7.3%) and with clomiphene in 4
(4.1%) cases. The median number of cycles per patient
was 1.85, with a range of 1–7. Fifty-eight per cent of
patients undergone only one procedure; the other 42%
had made between two and seven attempts, but in all
cases the type of procedure performed was the same.
Prophylaxis during ovarian stimulation procedures
and complications
Data regarding the prophylactic therapy of the ovarian
stimulation were available for 109 cycles (98.2%).
Seventy-one (65.1%) cycles were treated: 23 (32.4%)
with low-dose aspirin (LDA) only, 25 (35.2%) with a pro-
phylactic dose of low-molecular-weight heparin (LMWH)
and 23 (32.4%) with LDA plus prophylactic LMWH.
aPL were positive in 45 (40.5%) cycles: single positiv-
ity in 27, double in 13 and triple in 5. Of those cycles, 5
(2 single and 2 double positivity) were not subjected to
prophylaxis, and no thrombotic events were reported.
We registered three (3.1%) cases of ovarian hypersti-
mulation syndrome (OHSS), all after IVF procedures per-
formed with the agonist protocol. These patients were
affected by SLE, UCTD and Churg–Strauss vasculitis,
respectively. One of the patients (33.3%) presented ma-
jor risk factors for OHSS development (young age, low
body weight and polycystic ovary syndrome).
Outcome of procedures
Overall, 111 cycles yielded 46 pregnancies (41.4%), with
a pregnancy rate of 38.7% for homologous procedures
and 55.5% for heterologous procedures.
The global pregnancy rate was not influenced by
mean maternal age at the time of the procedure (35.7
years in women with successful procedures vs
36.9 years in women with unsuccessful procedures,
P¼0.20). An adjusted analysis with pregnancy as the
outcome (adjusting by fertility treatment, time under fer-
tility treatment, number of times with fertility treatment,
age, disease duration, thyroid alterations, etc.) was per-
formed and did not show any statistical significance.
Homologous procedures
IUI was effective in 8 (61.5%) cases, homologous IVF in
19 (46.3%) and homologous ICSI in 9 (23.1%). Procedures
performed during a natural cycle had a pregnancy rate of
87.5% (n ¼ 7/8), those with the agonist protocol of 28.6%
(n¼2/7), with the antagonist protocol of 48% (n¼12/25),
with the gonadotrophin-only protocol of 40% (n¼2/5) and
with the clomiphene protocol of 0%.
The pregnancy rate was higher in younger women
(mean age of 34.8 years in women with successful pro-
cedures vs 36.7 years in women with unsuccessful pro-
cedures, P¼0.05).
Heterologous procedures
Heterologous IVF were effective in 3/3 (100%) and het-
erologous ICSI in 7/14 (50%) cases. The single case of
embryo adoption was not effective.
The procedures performed during a natural cycle
showed a pregnancy rate of 71.4% (n¼5/7), those per-
formed with the agonist protocol of 16.7% (n¼1/6), with
the antagonist protocol of 0% (0/1), with the gonadotro-
phin-only protocol of 100% (n¼2/2) and with the clomi-
phene protocol of 100% (n: 2/2).
Mean maternal age at the time of the procedure did
not influence the pregnancy rate (39 years in women
with successful procedures vs 38.5 years in women with
unsuccessful procedures, P¼0.83).
We registered a mean number of transferred embryos
of 1.6 (median: 2; range: 1–4). A single embryo transfer
strategy was performed in 32 (31.2%) cases, with a preg-
nancy rate of 50%, whereas a multiple embryo transfer
was applied in 48 (68.8%) cycles, with a pregnancy rate of
39.6% (P¼0.37). The main variables (maternal age, auto-
antibodies, inherited thrombophilia, thyroid alterations, ma-
ternal disease, use of frozen or fresh embyos, and
hormonal stimulation) that could have influenced the effi-
cacy of the procedures were analysed, and we did not
find any statistical significance.
Pregnancy prophylaxis and outcome
A prophylactic therapy was administered in 35 (76.1%)
pregnancies: LDA in 9 (25.7%), prophylactic dosage of
LMWH in 4 (11.4%), therapeutic dosage of Unfrationated
Heparin in 1 (2.9%), LDA plus a prophylactic dosage of
LMWH in 20 (57.1%), and LDA plus a therapeutic dosage
of LMWH in 1 (2.9%).
Disease flares occurred in five (11.2%) pregnancies: four
articular (two in RA patients, two in SLE patients) and one
haematological (haemolytic anaemia in one SLE patient,
after spontaneous discontinuation of therapy). None of the
variables that could have influenced a flare onset (maternal
age, autoantibodies, inherited thrombophilia, thyroid altera-
tions, maternal disease, use of frozen or fresh embyos,
and hormonal stimulation) showed statistical significance.
No cases of thrombosis were reported.
Maternal complications other than flares and fetal–
neonatal complications are reported in Table 2.
Both fetal (P¼ 0.002) and neonatal (P¼0.01) complica-
tions were significantly higher in babies born from twin
pregnancies.
We recorded 4 (7.6%) fetal malformations; specifically,
one case of severe multiple malformations, 2 cases of par-
tial corpus callosum agenesis and 1 case of major cardiac
malformations. All malformations developed in twin preg-
nancies, carried by women affected by UCTD. The proce-
dures performed to induce the pregnancies burdened with
malformations were one IUI, one IVF and one ICSI. In two
of the three gestations, women received stimulation with
the agonist protocol, and in the other with the gonadotro-
phin-only protocol.
Regarding disease flares, none of the variables that
could have influenced the onset of maternal and fetal
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complications showed statistical significance. We found
a significantly higher incidence of fetal complications
only in twin pregnancies, as previously reported.
Pregnancies yielded 38 singleton and 7 twin live births
(for a total of 52 babies); 1 was lost to follow-up.
We report no miscarriages and 1 stillbirth for severe
multiple malformations. The live birth rate was 98%, but
we recorded 3 (6%) perinatal deaths in the first days of
life owing to complications of very severe prematurity
(24th, 25th and 29th weeks, respectively).
Puerperium
During the puerperium we recorded 1 (2.5%) post-
partum haemorrhage (uterine atony after a pre-term
caesarean section on the patient affected by EGPA, not
treated with anticoagulant therapy during pregnancy)
and 1 (2.5%) articular flare 3weeks after delivery in a
patient affected by RA who also experienced a disease
reactivation during pregnancy (etanercept administered
from the second trimester to 32weeks of gestation).
Subanalyisis of SLE and APS patients
We included in the study 58 cycles performed in 28
women affected by SLE and/or primary APS (20 SLE, 2
SLEþAPS and 6 primary APS). Infertility was primary in
19 (68%) women and secondary in 9 (32%). Underlying
causes of infertility were of female origin in 2 cases
(7.1%), of male origin in 3 (10.8%), mixed in 1 (3.5%)
and unknown in 22 (78.6%). Four patients had been ex-
posed to CYC, and 1 (25%) of them had a premature
ovarian failure. A subanalysis, adjusted by age and CYC
treatment, did not show any statistical significance.
The median number of cycles performed per patient
was 2.1, with a range of 1–5.
Ten procedures (17.2%) were performed during natural
cycles, 48 (82.8%) after ovarian stimulation (30 with GnRH
agonist, 12 with GnRH antagonist, 2 with clomiphene, and
4 with the gonadotrophin-only protocol). Overall, the 58
cycles yielded 18 pregnancies (16 singleton, 2 twin), with
a global pregnancy rate of 31% (25.6% in homologous
and 46.7% in heterologous procedures). No thrombotic
events were reported. An OHSS onset was observed in 1
(2%) cycle (SLE patient after IVF with the agonist proto-
col), and a disease flare was recorded in 3 (5.1%) cases
(all SLE patients: 2 mild articular flare, and 1 haematologi-
cal flare after spontaneous discontinuation of therapy).
Maternal, fetal and neonatal complications are
reported in Table 2.
We report no miscarriages. The live birth rate was
100%, but we recorded two (10%) perinatal deaths in
the first days of life, owing to complications of very se-
vere prematurity (24th and 29th weeks, respectively).
An adjusted analysis of flares by fertility treatment,
age and disease duration in this sub-population could
not be performed, owing to the small sample size.
TABLE 2 Complications and neonatal features in the whole cohort and in the SLE/APS subgroup
Complication Whole cohort (46 pregnancies) SLE/APS patients (18 pregnancies)
Maternal complications 13 (30.2) 6 (33.3)
Gestational diabetes, n (%) 4 (8.7) 0
Thrombocytopenia, n (%) 2 (4.3) 2 (11.1)
Pre-eclampsia, n (%) 2 (4.3) 1 (5.5)
Placenta praevia, n (%) 2 (4.3) 2 (11.1)
Gestational hypothyroidism, n (%) 1 (2.1) 0
Gestational hypertension, n (%) 1 (2.1) 1 (5.5)
Cholestasis of pregnancy, n (%) 1 (2.1) 0
Whole cohort (52 neonates) SLE/APS patients (20 neonates)
Fetal complications 11 (21.1) 5 (25)
IUGR, n (%) 3 (5.8) 2 (10)
Oligo/anhydramnios, n (%) 3 (5.8) 3 (15)
SGA neonate, n (%) 1 (1.9) 0
Fetal malformationsa, n (%) 4 (7.7) 0
Neonatal complications 5 (1) 0
Neonatal hypoglycaemia, n (%) 1 (20) 0
Respiratory distress syndrome, n (%) 2 (40) 0
Intestinal resection due to ischaemia, n (%) 1 (20) 0
Neonatal jaundice, n (%) 1 (20) 0
Gestational week at delivery, median (IQR) 38 (37–39) 37 (36–38)
At term deliveries, n (%) 38 (84.4)b 14 (77.8)
Birth weight, median (IQR), g 3005 (2501–3270) 2860 (2342–3148)
Birth length, median (IQR), cm 49 (46–51) 48.5 (45–50)
aDetails in the text.
bOne woman lost to follow-up.
Abbreviations: IQR: interquartile range; IUGR: intrauterine growth restriction; SGA: small for gestational age.
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Discussion
ARTs performed in rheumatic patients raise two important
questions: whether they could confer risks additional to
those reported for the general population (because they
often require hormonal stimulation with gonadotrophins,
which determine an oestrogenic peak) and whether, if per-
formed, their effectiveness is affected by maternal disease.
In order to answer to both these questions, we
analysed a case series of 111 ART procedures per-
formed in a multicentre cohort of 60 rheumatic women.
The safety of the procedures seems to be assured by
the fact that no case of thrombosis has been registered
during hormonal stimulation or throughout pregnancy and
the puerperium. This finding is even more reassuring con-
sidering that !40% of the procedures have been per-
formed in aPL-positive women. We registered 3 (3.1%)
cases of OHSS; this incidence is in line with that reported
in the general population (3–8% of cycles, with peaks of
20% in high-risk categories [34]) and with data published
in SLE and APS patients (0–6.2% [23–27] vs 2% in this
subpopulation in our cohort). Disease flares were registered
in 12.5% of pregnancies, with a higher frequency (albeit
not significant) in women with CTDs and vasculitis than in
those with arthritis, as reported for natural pregnancies
[35]. No correlation with any of the potential precipitating
factors, such as disease phenotype, autoantibody positivity
and prophylactic therapy administered, has been found.
To compare our data with those previously published,
we extracted the SLE and APS subpopulation from our
cohort, and we noticed that during the 58 cycles per-
formed in these patients only 3 (5.2%) disease flares
were recorded, in line with what has been reported in
the two most recently published cohorts [23, 27] (6.1%)
and significantly lower than in the 3 older studies [24–
26] (16–37.5%) [35].
Maternal complications other than disease flare devel-
oped in about one-third of the pregnancies. The incidence
is not negligible, but it is consistent with that reported in
the general population after ARTs; in particular: gestational
diabetes in 8.7% of the pregnancies (vs 6–7% in the gen-
eral population) [36] and gestational hypertension in 2.2%
(vs 6–13%) [37]. A higher rate of maternal complications
has been found after the transfer of frozen embryos (57 vs
21%), as reported in healthy women [38] and in patients
affected by CTDs (10 vs 5% in those with arthritis).
Fetal complications were experienced in 22% of preg-
nancies and, not surprisingly, they were significantly
more frequent in aPL-positive women (44 vs 10%) and
during multiple pregnancies (57 vs 15.4%).
Regarding the efficacy of the procedures in rheumatic
patients, the data seem to be satisfactory, with a cumu-
lative pregnancy rate of 41.4%.
Analysing the possible influence of autoimmunity on
the efficacy of the procedures, we cannot confirm the
apparent negative role played by ANA and ENA antibod-
ies previously reported in the literature [39].
The positivity for aPL does not seem to be a negative
prognostic factor for the efficacy of procedures, and the
administration of LDA and/or LMWH does not seem to
improve the pregnancy rate. The prophylaxis is, how-
ever, indicated to protect the woman from thrombotic
complications [20, 40].
The pregnancy rate registered in SLE and APS
women was 37.5%, slightly higher than those previous
reported (16–31%) [23–27], and the live birth rate was
100%, far above those recorded so far (50–87%) [23–
27]. The cumulative live birth rate for the study was
98%, demonstrating that a tight control strategy, based
on a multi-specialist follow-up of the pregnancy and the
administration of correct prophylaxis, provides signifi-
cant success rate.
Although the present study has clear limitations,
mainly attributable to the small sample size, the lack of
a control group and the inclusion of different protocols,
some important points seem to emerge: the safety and
the efficacy of the ARTs seems to be confirmed in rheu-
matic patients, regardless of their autoimmune profile;
thromboprophylaxis during ovarian stimulation and, if
appropriate, during pregnancy, seems to protect
patients against the increased risk connected to the
oestrogenic peak, although it did not improve pregnancy
rate: the choice of therapy should therefore be made
depending on the patient risk profile, irrespective of
whether the pregnancy is natural or artificially induced;
the rate of fetal–maternal complications is in line with
that observed in the general population after ARTs and
in spontaneous gestation in rheumatic patients,
indicating that the disease itself, rather than the proce-
dure applied, is probably the cause of their onset;
maternal disease flares were mild or moderate in sever-
ity, without any influence on gestational outcome; in lu-
pus patients, the incidence of flares was lower than that
reported in spontaneous gestations, suggesting that the
flare onset is probably determined by the pregnancy it-
self rather than by ARTs; a single embryo transfer strat-
egy should be recommended in order to avoid twin
pregnancies and improve gestational outcomes.
The main achievement of this multicentre study is that
no evidence was found to advise against the application
of ARTs in rheumatic patients. Pre-conception
counselling is essential to determine the best time for
pregnancy, to adjust the prophylactic treatment and to
ensure the best gestational outcome [41]. No additional
or closer monitoring than that applied in natural preg-
nancies seems to be needed in women with RDs.
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